NCT07126171

A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Jiangsu Kanion Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of Reduning Injection in the treatment of chikungunya fever

Detailed description

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study of the efficacy and safety of Reduning Injection in the treatment of Chikungunya fever. The purpose of this study is to evaluate the efficacy and safety of Reduning Injection in the treatment of Chikungunya fever. The study uses the IWRS system to randomize the study participants, adopts the double-blind method, selects placebo control, plans to be conducted simultaneously in multiple research centers across the country, plans to include 400 study participants, and randomly assigns them to the test drug group and the placebo group at a 1:1 ratio, with 200 participants in the test drug group.

Conditions

• Chikungunya Fever

Interventions

Type	Name	Description
DRUG	Reduning injection	reduning Injection, intravenous drip, 20 ml per time, once a day;
DRUG	The simulant of Reduning Injection	The simulant of Reduning Injection, for intravenous drip, 20 ml per time, once a day

Timeline

• Start date: 2025-08-28
• Primary completion: 2025-11-26
• Completion: 2026-02-18
• First posted: 2025-08-17
• Last updated: 2025-08-17

Locations

1 site across 1 country: China